- Home
- ZDGE vs INTS Comparison
ZDGE vs INTS Comparison
Compare ZDGE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- INTS
- Stock Information
- Founded
- ZDGE 2008
- INTS 2012
- Country
- ZDGE United States
- INTS United States
- Employees
- ZDGE N/A
- INTS N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ZDGE Technology
- INTS Health Care
- Exchange
- ZDGE Nasdaq
- INTS Nasdaq
- Market Cap
- ZDGE 40.3M
- INTS 33.4M
- IPO Year
- ZDGE N/A
- INTS 2023
- Fundamental
- Price
- ZDGE $2.65
- INTS $2.23
- Analyst Decision
- ZDGE
- INTS Strong Buy
- Analyst Count
- ZDGE 0
- INTS 3
- Target Price
- ZDGE N/A
- INTS $8.50
- AVG Volume (30 Days)
- ZDGE 58.5K
- INTS 26.6K
- Earning Date
- ZDGE 03-14-2025
- INTS 03-13-2025
- Dividend Yield
- ZDGE N/A
- INTS N/A
- EPS Growth
- ZDGE N/A
- INTS N/A
- EPS
- ZDGE N/A
- INTS N/A
- Revenue
- ZDGE $30,204,000.00
- INTS N/A
- Revenue This Year
- ZDGE $0.34
- INTS N/A
- Revenue Next Year
- ZDGE $6.35
- INTS N/A
- P/E Ratio
- ZDGE N/A
- INTS N/A
- Revenue Growth
- ZDGE 10.15
- INTS N/A
- 52 Week Low
- ZDGE $1.93
- INTS $1.50
- 52 Week High
- ZDGE $4.69
- INTS $5.94
- Technical
- Relative Strength Index (RSI)
- ZDGE 44.69
- INTS 49.26
- Support Level
- ZDGE $2.65
- INTS $1.84
- Resistance Level
- ZDGE $2.89
- INTS $2.27
- Average True Range (ATR)
- ZDGE 0.16
- INTS 0.28
- MACD
- ZDGE -0.02
- INTS -0.01
- Stochastic Oscillator
- ZDGE 30.61
- INTS 56.36
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.